Brain Cancer Archives - Neurology Advisor

2008 to 2017 Saw Decrease in Malignant Brain Tumor Incidence

September 13, 2021

From 2008 to 2017, the incidence of malignant brain tumors decreased for all ages combined, but increased among children and adolescents.

Brain Tumors

Combination Immunotherapy Effective for Patients With Melanoma and Asymptomatic Brain Metastases

By

Amit Akirov, MD

May 17, 2021

The combination of nivolumab with ipilimumab is an effective treatment option for patients with advanced melanoma with asymptomatic brain metastases

Brain Tumors

Occult Brain Metastasis Detected in Patients With Advanced Renal Cancer

May 5, 2021

Occult brain metastasis is identified in about 4 percent of patients with metastatic renal cell carcinoma (mRCC).

Brain Tumors

Socioeconomics Tied to Cognitive Function in Survivors of Childhood Brain Tumors

By

Victoria Forster, PhD

April 13, 2021

Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status.

Brain Tumors

Laser-Based Imaging and Artificial Intelligence May Diagnose Brain Tumors in OR

January 13, 2020

A novel workflow that combines advanced optical imaging with an artificial intelligence algorithm may accurately diagnose brain tumors in real time in the operating room.

General Neurology

Non-melanoma Skin Cancers Are Less Likely to be Treated in Elderly Patients

By

Brandon May

October 9, 2019

Unlike previous studies, the researchers found that in their practice, no-treatment rates between elderly and nonelderly patients with biopsy-proven NMSCs were significantly different.

Brain Tumors

Outcomes Poor Years After Radiation for Pediatric Glioma Survivors

July 3, 2019

Survivors of childhood low-grade gliomas treated with radiotherapy have poorer neuropsychological and socioeconomic-status outcomes.

Brain Tumors

Phase 3 Study of Investigative Glioblastoma Treatment Halted

By

Steve Duffy

May 21, 2019

AbbVie has halted enrollment in all ongoing studies of depatuxizumab mafodotin, after an Independent Data Monitoring Committee (IDMC) recommended a phase 3 study of the treatment be stopped due to a lack of survival benefit.